Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases
Phase 1/2 Terminated
8 enrolled 13 charts
PRO1107 in Patients With Advanced Solid Tumors
Phase 1/2 Terminated
33 enrolled
Topical Dermaprazole for Radiation Dermatitis in Breast Cancer Patients (TOPAZ)
Phase 1/2 Terminated
3 enrolled 8 charts
Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer
Phase 1/2 Terminated
34 enrolled 15 charts
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Phase 1/2 Terminated
61 enrolled 29 charts
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Phase 1/2 Terminated
73 enrolled
AMEERA-1
Phase 1/2 Terminated
136 enrolled 60 charts
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
Phase 1/2 Terminated
31 enrolled
A Study of PF-06873600 in People With Cancer
Phase 1/2 Terminated
155 enrolled 44 charts
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Phase 1/2 Terminated
137 enrolled 31 charts
Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body
Phase 1/2 Terminated
1 enrolled 5 charts
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
Phase 1/2 Terminated
175 enrolled
Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC
Phase 1/2 Terminated
10 enrolled 15 charts
A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer
Phase 1/2 Terminated
9 enrolled 21 charts
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
Phase 1/2 Terminated
19 enrolled
Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer
Phase 1/2 Terminated
5 enrolled
Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer
Phase 1/2 Terminated
6 enrolled 11 charts
AVID100 in Advanced Epithelial Carcinomas
Phase 1/2 Terminated
49 enrolled 19 charts
Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test
Phase 1/2 Terminated
10 enrolled 11 charts
neoBREASTIM
Phase 1/2 Terminated
2 enrolled
A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors
Phase 1/2 Terminated
52 enrolled 33 charts
Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer
Phase 1/2 Terminated
9 enrolled 7 charts
ELONA
Phase 1/2 Terminated
4 enrolled
A Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and Gastro-Esophageal Junction (GEJ) Cancer
Phase 1/2 Terminated
13 enrolled 18 charts
Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients
Phase 1/2 Terminated
15 enrolled
A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors
Phase 1/2 Terminated
40 enrolled 20 charts
A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors
Phase 1/2 Terminated
6 enrolled
A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors
Phase 1/2 Terminated
70 enrolled 24 charts
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
Phase 1/2 Terminated
15 enrolled
Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer
Phase 1/2 Terminated
46 enrolled
RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer
Phase 1/2 Terminated
5 enrolled 6 charts
Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors
Phase 1/2 Terminated
7 enrolled
QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.
Phase 1/2 Terminated
9 enrolled 18 charts
QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer
Phase 1/2 Terminated
3 enrolled 6 charts
A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies
Phase 1/2 Terminated
3 enrolled 9 charts
Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
Phase 1/2 Terminated
3 enrolled
CamBMT1
Phase 1/2 Terminated
26 enrolled
Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies
Phase 1/2 Terminated
79 enrolled 22 charts
PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors
Phase 1/2 Terminated
99 enrolled 21 charts
A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours
Phase 1/2 Terminated
6 enrolled
Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors
Phase 1/2 Terminated
223 enrolled 50 charts
T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery
Phase 1/2 Terminated
12 enrolled 16 charts
Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca
Phase 1/2 Terminated
27 enrolled 12 charts
NBE-002 in Patients With Advanced Solid Tumors
Phase 1/2 Terminated
12 enrolled
Ixabepilone and Hydroxychloroquine in Treating Patients With Metastatic Breast Cancer
Phase 1/2 Terminated
6 enrolled 7 charts
Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer
Phase 1/2 Terminated
1 enrolled 6 charts
GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors
Phase 1/2 Terminated
48 enrolled 29 charts
A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors
Phase 1/2 Terminated
48 enrolled 20 charts
REVEAL
Phase 1/2 Terminated
64 enrolled 22 charts
PEER
Phase 1/2 Terminated
16 enrolled